Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.59 |
| ▸ | PPARA | Q07869 | 17/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935844 | 0.84 | SMN1; SMN2 (0.70) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL8935859 | 0.84 | SMN1; SMN2 (0.70) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL1171344 | 0.84 | SMN1; SMN2 (0.70) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL5512522 | 0.83 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL11589516 | 0.82 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL27875516 | 0.81 | ALDH1A1 (0.55) | PPARGPPARASMN1; SMN2L3MBTL1 | |
| SCHEMBL4257140 | 0.81 | PPARG (0.65) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL6162499 | 0.81 | PPARG (0.69) | PPARGPPARA | |
| SCHEMBL23606001 | 0.80 | L3MBTL1 (0.49) | PPARGPPARAL3MBTL1 | |
| SCHEMBL4187784 | 0.79 | L3MBTL1 (0.47) | PPARGPPARAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045414-B2 | Pyrrolidin-2-ones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9045414-B2 | Pyrrolidin-2-ones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| EP-2346852-B1 | PYRROLIDIN-2-ONES AS HDM2 LIGANDS | BOEHRINGER INGELHEIM INT (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20120122839-A1 | NOVEL PYRROLIDIN-2-ONES | PRIAXON AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122839-A1 | NOVEL PYRROLIDIN-2-ONES | PRIAXON AG (DE) | 2012-05-17 | — | — | US | disclosed |
| US-8119623-B2 | Pyrrolidin-2-ones | PRIAXON AG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119623-B2 | Pyrrolidin-2-ones | PRIAXON AG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100075949-A1 | NOVEL PYRROLIDIN-2-ONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100075949-A1 | NOVEL PYRROLIDIN-2-ONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| WO-2010028862-A1 | PYRROLIDIN-2-ONES AS HDM2 LIGANDS | PRIAXON AG (DE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075949-A1 | NOVEL PYRROLIDIN-2-ONES | ING2, HMGB2, API5 | PPARG 1603/4885PPARA 1542/4885SMN1; SMN2 113/4885 |
| US-20120122839-A1 | NOVEL PYRROLIDIN-2-ONES | ING2, HMGB2, API5 | PPARG 1603/4885PPARA 1542/4885SMN1; SMN2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.